- Home
- EQX vs BMRN Comparison
EQX vs BMRN Comparison
Compare EQX & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | BMRN |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.4B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | EQX | BMRN |
|---|---|---|
| Price | $12.22 | $64.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 18 |
| Target Price | $17.00 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 14.8M | 2.2M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $102.84 | $15.02 |
| Revenue Next Year | $15.55 | $12.23 |
| P/E Ratio | $137.41 | ★ $84.71 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $8.49 | $49.26 |
| 52 Week High | $18.96 | $70.98 |
Technical Indicators
Market Signals| Indicator | EQX | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 50.10 |
| Support Level | $11.75 | $58.03 |
| Resistance Level | $13.79 | $66.28 |
| Average True Range (ATR) | 0.50 | 1.55 |
| MACD | -0.04 | -0.58 |
| Stochastic Oscillator | 41.67 | 7.64 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.